Trial Profile
A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 (1.0% Azithromycin and 0.1% Dexamethasone) Compared to AzaSite Alone, Dexamethasone 0.1% Alone, and Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Azithromycin/dexamethasone (Primary) ; Azithromycin; Dexamethasone
- Indications Blepharitis
- Focus Registrational; Therapeutic Use
- Acronyms DOUBle
- Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries
- 08 Apr 2014 New trial record